
    
      Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics
      and Pharmacodynamics of Intravenous AZD3043 after a Single Ascending Bolus Dose Followed by a
      Single Infusion Dose in Elderly (=65 years) Healthy Volunteers
    
  